The RhoA/Rho-kinase cascade is involved in various cellular functions, including migration, proliferation, and smooth muscle contraction. We examined the potential role of this pathway in oxytocin-induced uterine contraction. The specific Rho-kinase inhibitor Y-27632 inhibited oxytocin-induced rat uterine contraction on d 21 of pregnancy in a concentration-dependent manner, whereas the extent of this inhibition was reduced in the nonpregnant uterus. Y-27632 had no effect on oxytocin-induced intracellular Ca 
R HYTHMIC UTERINE CONTRACTIONS play an im-
portant role in parturition. Oxytocin and PGs are powerful stimulators of uterine contraction and increases in the number of receptors for these substances during pregnancy are believed to augment the uterine contractility at term (1, 2) . These substances not only induce intracellular Ca 2ϩ mobilization but also enhance the Ca 2ϩ sensitivity of the myometrium through a G protein-mediated mechanism (3, 4) . However, the precise intracellular mechanism of augmentation of uterine contractility still remains to be elucidated.
In recent years, there have been remarkable advances in our knowledge of the biochemical mechanisms underlying smooth muscle contractility. It is widely accepted that a rise in the concentration of intracellular free Ca 2ϩ ([Ca 2ϩ ] i ) is the major trigger for smooth muscle contraction (5, 6) , and that the degree of myosin light chain (MLC) phosphorylation by the Ca 2ϩ /calmodulin-dependent enzyme MLC kinase is the essential factor that determines the extent of smooth muscle contraction (7) . MLC phosphorylation results in smooth muscle contraction, whereas MLC dephosphorylation by myosin phosphatase results in muscle relaxation (8) . However, studies using Ca 2ϩ indicators to measure [Ca 2ϩ ] i revealed that the Ca 2ϩ concentration does not always parallel the degree of MLC phosphorylation and contraction (5) . The extent of MLC phosphorylation or force of contraction induced by agonist stimulation is higher than that of increase in [Ca 2ϩ ] i , and this phenomenon is known as "Ca 2ϩ sensitization" (5, 7) .
Although the mechanism underlying Ca 2ϩ sensitization has not been fully elucidated, several lines of evidence indicated that the small GTPase Rho, a member of the Rho subfamily of the Ras superfamily of monomeric GTPases, is responsible for the Ca 2ϩ sensitization induced by agonist stimulation (9, 10) . The small GTPase Rho is involved in various cellular functions, including stress-fiber and focaladhesion formation, cell morphology, cell motility, membrane ruffling, and smooth muscle contraction (11) . The activated Rho increased the MLC phosphorylation at a constant Ca 2ϩ concentration, which suggested that Rho was involved in the regulatory mechanism of the Ca 2ϩ sensitivity (12) . While several proteins have been identified as effectors of Rho, including protein kinase N, peroxidase-coupled antigoat antibody (Rho-kinase), rhophilin, rhotekin, citron, p140 mDia, and citron kinase (13) , recent analyses revealed that the signaling pathway that involves Rho-kinase plays a crucial role in the Ca 2ϩ sensitization of smooth muscle contraction by inhibiting the activity of myosin phosphatase (14, 15) . Smooth muscle myosin phosphatase consists of a 38-kDa catalytic subunit, the 130-kDa myosin-binding subunit (MBS), and a 21-kDa subunit (16, 17) . MBS was originally identified as a substrate of Rho-kinase (18) , and myosin phosphatase binds to the phosphorylated MLC via MBS and dephosphorylates MLC. These studies showed that RhoA regulates MLC phosphorylation through its target protein, Rhokinase, which phosphorylates the MBS of myosin phosphatase and thereby inhibits the activity of this phosphatase (14, 19) .
Although the heteromeric G proteins of the myometrium have been reported to change during pregnancy (20, 21) in myometrium during pregnancy have not been characterized. Recently the detection of RhoA and Rho-kinase in the pregnant myometrium has been reported (22, 23) , which suggests that the RhoA/Rho-kinase system plays a role in uterine smooth muscle contraction. However, the expressions and functions of these proteins in myometrium have not been fully examined at the pharmacological or molecular level.
In the present study, we examined the potential role of the RhoA/Rho-kinase pathway in oxytocin-induced uterine contraction by using a specific Rho-kinase inhibitor, Y-27632. Y-27632 has been developed and reported to inhibit the kinase activity of Rho-kinase specifically in a manner competitive with ATP (24) . This inhibitory probe for Rho-kinase is very useful and enables the evaluation of the physiological roles of Rho-kinase in intact smooth muscle. We demonstrated here whether Y-27632 inhibits oxytocin-induced uterine contraction. Furthermore, the involvement of MLC and MBS phosphorylation in the effect of oxytocin and Y-27632 was investigated. We also determined the expression of RhoA and Rho-kinase in the rat uterus during the course of pregnancy compared with the nonpregnant uterus. These results suggest that the RhoA/Rho-kinase pathway may have an important role in the enhancement of contractility.
Materials and Methods Reagents
Mouse monoclonal antibody to myosin light chain (MLC 20 ) was purchased from Sigma (St. Louis, MO). Anti-Ser19-phosphorylated MLC monoclonal antibody (pCL1) was a generous gift from Dr. M. Seto (Asahi Chemical Industry Company, Japan) (25) . Polyclonal antibody against rat MBS and polyclonal anti-pS854 antibody were kindly provided by Dr. K. Kaibuchi (Nagoya University) (26) . Anti-RhoA (26C4) and Rock-2 (C20) antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-GAPDH antibody was purchased from Biogenesis Ltd. (Kingston, NH). Peroxidase-conjugated antimouse, antirabbit and antigoat IgG were from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). Enhanced chemiluminescence (ECL) Western blotting detection reagents were obtained from Amersham Pharmacia Biotech (Arlington Heights, IL). Membrane-permeant Ca 2ϩ indicator dye acetoxymethyl ester fura-2 (fura-2 AM) was purchased from Molecular Probes, Inc. (Eugene, OR). Y-27632, a specific inhibitor of Rho-kinase, was kindly provided by WelFide Corp. (Osaka, Japan). Y-27632 was dissolved in distilled water as stock solution (10 mm 
Isometric recordings of myometrial contraction
Experiments were performed on uteri from 8-wk-old Wistar female rats (nonpregnant, 200 g; pregnant, primipara, d 21 of pregnancy). All protocols were in accordance with the National Institutes of Health Guidelines and approved by the Animal Care and Use Committee of Osaka University School of Medicine. Animals were anesthetized with ether and killed by cervical dislocation. Uterine horns were obtained from pregnant (d 21) or nonpregnant rats and were cut into longitudinal strips approximately 1 cm long and 1 mm wide. These strips were mounted for isometric recording under 1 g tension in normal Tyrode's solution at 37 C, gassed with 95% O 2 /5% CO 2 and equilibrated under these conditions for 1 h. The mechanical responses were measured as integrated tension by means of a force displacement transducer. Uterine strips were exposed to Tyrode's solution containing oxytocin (0.2 nm) to induce phasic contractions. After 20 min of equilibration, Y-27632 was added in a cumulative manner to the bath at 20-min intervals. Control experiments were run in parallel in which the same amount of the vehicle (distilled water) for Y-27632 was added to the strips at the same intervals as the Y-27632 application. The relaxant effect was assessed by expressing the integrated tension during the 20-min period after the addition of each drug concentration as a percentage of the tension in the 20-min period before drug addition.
Measurement of intracellular Ca 2ϩ
Uterine myocytes were prepared by the method of Masumoto and colleagues (27, 28) . Longitudinal muscles of pregnant (d 21) rats were cut into several pieces (1 ϫ 1 mm), and incubated in HBSS containing 0.1% collagenase at 37 C for 25 min. Dispersed cells were suspended in DMEM with 10% FBS and plated on poly-l-lysine-coated 35-mm glass-bottomed dishes (MatTek Co., Ashland, MA). Cells were loaded with the membrane-permeant Ca 2ϩ indicator dye fura-2 AM (1 m), then rinsed and maintained in fura-2-free solution before beginning data acquisition. Cells on coverslips were excited with a mercury lamp through 340-and 380-nm band-pass filters, and emitted fluorescence at 510 nm was detected with a digital imaging fluorescence microscope (Hamamatsu Photonics, Hamamatsu, Japan). After subtracting the background signal, the ratio of 340/380 emissions at 510 nm was used as an indicator of 
Immunoblot analysis for detection of MLC and MBS phosphorylation
The levels of phosphorylation of MLC and MBS were assessed in frozen strips to avoid the influence of cyclical phosphorylation-dephosphorylation reactions accompanying myometrial contractions as follows; uterine horns were obtained from pregnant (d 21) Wistar rats and were cut into longitudinal strips approximately 1 cm long and 1 mm wide. The strips were mounted for isometric recording as described above. The contraction induced by oxytocin (0.2 nm) was then examined, and the specimens were removed from the hook at the time of maximal contraction and immediately frozen by immersion in 90% acetone-10% trichloroacetic acid (TCA) containing 10 mm dithiothreitol (DTT) cooled with dry ice, and then homogenized in 10% TCA containing 10 mm DTT. The homogenate was centrifuged at 15,000 ϫ g at 4 C for 5 min and the supernatant was carefully removed. The pellet was washed with ice-cold acetone containing 10 mm DTT three times, and after the third wash, the remaining acetone was allowed to completely evaporate for 10 min, while the sample was kept on ice. The dried samples were cut into small pieces and mixed with SDS sample buffer, sonicated for 10 sec on ice three times, heated at 100 C for 5 min, and centrifuged at 15,000 ϫ g for 5 min. An aliquot was retained for protein assay using the method of Lowry.
To evaluate the effects of the Rho-kinase inhibitor Y-27632 on phosphorylation of MLC or MBS, the uterine strips were preincubated with Y-27632 (10 Ϫ5 m) for 10 min and then stimulated without removal of Y-27632. The specimens were removed from the hook and immediately frozen at the same time as the corresponding specimens without Y-27632 were frozen, and treated as described above.
For the detection of the degree of MLC phosphorylation, the extracted samples (20 g protein in each sample) were separated by SDS-PAGE and blotted onto polyvinylidenedifluoride membranes, and then the membranes were immunologically probed separately with antiphosphorylated MLC antibody (25) and with anti-MLC 20 antibody. The signals were detected with ECL reagents, and quantitative densitometric analysis of immunoblots was performed using Fluor Chem IS-8000 (Alpha Innotech Corp., San Leandro, CA). The degree of MLC phosphorylation were calculated by dividing the densitometric values of the phosphorylated MLC signal by those of MLC 20 signal. For the detection of the degree of MBS phosphorylation, the membranes were immunologically probed separately with anti-pS854 antibody and anti-MBS antibody. One of the major sites for phosphorylation of MBS by Rho-kinase both in vitro and in vivo has been identified as Ser-854, and the antibody we used specifically recognizes MBS phosphorylated at Ser-854 (26) . The degree of MBS phosphorylation was calculated by dividing the densitometric values of pS854 signal by those of MBS signal.
Identification of RhoA/Rho-kinase proteins by immunoblot analysis
For detection of RhoA and Rho-kinase proteins in rat myometrium, samples were prepared as follows: myometrial tissues were obtained from nonpregnant and pregnant (d 12, 18, 21) rats, and were cut into longitudinal strips approximately 1 cm long and 1 mm wide. These tissues were immediately frozen and extracted by TCA/acetone as described above. Samples (20 g protein in each sample) were separated by SDS-PAGE (7.5 or 12%). Proteins were transferred to polyvinylidenedifluoride membranes and probed with anti-RhoA (26C4) and antiRock-2 (C-20) antibodies. Rock-2 (C-20, Santa Cruz Biotechnology, Inc.) is raised against epitope mapping at the carboxy terminus of rat Rock-2 (also designated Rho-kinase). Immunoblots were developed using ECL reagents. The same membranes were re-probed with anti-GAPDH antibody (29) and used as a control to ascertain that equivalent amounts of proteins had been transferred. Quantitative densitometry of immunoblots was performed using Fluor Chem IS-8000 (Alpha Innotech Corp.). For the quantitative analysis, the densitometric values were normalized to GAPDH, and then the ratios of RhoA or Rho-kinase/ GADPH were expressed as the fold increases from those of nonpregnant samples. The results from five studies were analyzed.
Identification of RhoA/Rho-kinase mRNA by RT-PCR and Northern blot analysis
Myometrial tissues were obtained from nonpregnant and pregnant (d 12, 18, 21) rats, and were immediately frozen. RNA was extracted from the tissues using TRIzol reagent, and any contaminating genomic DNA was digested by RNase-free DNase. Total RNA (1 g) was used as the template for the reverse transcriptase (RT) reaction by using SuperScript II following the manufacturer's instructions. An aliquot (5 l) of RT product was used for PCR amplification in a total volume of 50 l. The primers used in RT-PCR for RhoA, Rho-kinase and GADPH were as follows: RhoA sense 5Ј-ACC AGT TCC CAG AGG TTT ATGT-3Ј, antisense 5Ј-TTT GGT CTT TGC TGA ACACT-3Ј; Rho-kinase sense 5Ј-GCA CAT GTA TGA AAA TGG ATG AAAC-3Ј, antisense 5Ј-CAT AAT TTT GCT GTA GGT TCC TAC AAGT-3Ј; GADPH sense 5Ј-ACC ACA GTC CAT GCC ATC AC-3Ј, antisense 5Ј-TCC ACC ACC CTG TTG CTG TA-3Ј. The thermal cycle profile used in this study was (1) denaturing for 30 sec at 94 C (2), annealing primers for 90 sec at 55 C, and (3) extending the primers for 30 sec at 72 C. The sequence of the primer for RT-PCR analysis of RhoA and Rho-kinase used in this study was reported previously by Nishimura et al. (30) . PCR amplification for RhoA and Rho-kinase was performed for 30 cycles and that for GAPDH (as an internal control) was performed for 25 cycles. These amplifications were performed in the range of the linear relationship between the cycle number and the intensity of RT-PCR product (data not shown). A portion (10 l) of the PCR mixture was electrophoresed in a 1.5% agarose gel in TAE buffer (40 mm Tris-acetate, pH 8.5, 2 mm EDTA). The gel was stained with ethidium bromide and then photographed.
For Northern blot analysis, poly(A) ϩ RNAs were isolated using the PolyA tract mRNA Isolation System (Promega Corp., Madison, WI), and 10 g of poly(A) ϩ RNA were electrophoresed on a 1% agarose/formaldehyde gel. After transfer to a Hybond-XL nylon membrane (Amersham Pharmacia Biotech, Arlington Heights, IL) and UV cross-linkage, poly(A) ϩ RNAs were hybridized at 65 C in UltaHyb solution (Ambion, Inc. Austin, TX). cDNA probes for RhoA and Rho-kinase were kindly provided by Dr. K. Kaibuchi (Nagoya University). A BamHI fragment (900-bp) from pEXV vector containing the full-length RhoA cDNA and a BamHI-and BglII-digested fragment (1.3 kb) from pEXV vector containing full-length Rho-kinase cDNA were labeled with [
32 P]deoxy-CTP by random-primed synthesis. GAPDH cDNA probe was used as a control to ascertain that equivalent amounts of mRNA had been transferred. Blots were washed under standard high-stringency conditions (final wash: 42 C, 0.1% SSC, 0.1% SDS) and exposed to Fuji Photo Film Co., Ltd. Medical x-ray Film with an intensifying screen at Ϫ70 C. The radioactivity of each band was quantified using a BAS2000 imaging system (Fuji Photo Film Co., Ltd. Film, Tokyo, Japan). For the quantitative analysis, the radioactivities of RhoA and Rho-kinase bands were normalized to those for GAPDH, and then the ratios of RhoA or Rho-kinase/GADPH were expressed as the fold increases from those of nonpregnant samples. The results from three studies were analyzed.
Statistical analysis
The results are expressed as means Ϯ sem. Statistical analysis was performed with unpaired t test in the organ chamber experiment, and with one-way ANOVA and subsequent Scheffé's post hoc test in the other experiments. P Ͻ 0.05 was considered to indicate a statistical difference.
Results

Effect of Y-27632 on oxytocin-induced contraction
To determine the role of the RhoA/Rho-kinase pathway in rat uterine contraction, we first examined whether the Rhokinase inhibitor Y-27632 inhibits oxytocin-induced uterine contraction using pregnant (d 21) rat myometrial tissues. Figure 1A shows a recording of oxytocin-induced myometrial contractility, and the effect of Y-27632. Oxytocin (0.2 nm) increased contractile activity compared with spontaneous activity, and Y-27632 reduced force in all preparations studied. The inhibitory effect of Y-27632 was observed within 5 min, and both of amplitude and frequency of contraction were decreased dose dependently. With 10 Ϫ4 m Y-27632, contractile activity was essentially abolished. Under control condition in which the same amount of the vehicle (distilled water) for Y-27632 was added to the strips at the same intervals as the Y-27632 application, consistent amplitude and frequency were recorded for several hours (data not shown). After application of the maximum dose of Y-27632 (10 Ϫ4 m), the contractility was reversed immediately by washing the strips with medium containing oxytocin (Fig. 1A) . Figure 1B shows the dose-response relationship of Y-27632 and oxytocin-induced uterine contraction: Y-27632 inhibited phasic contraction induced by oxytocin in a concentration-dependent manner. These results indicate that Rho-kinase was involved in oxytocin-induced uterine contraction. We also examined the effect of Y-27632 in the nonpregnant uterus. The sensitivity to Y-27632 in nonpregnant uterus was significantly decreased by 3 ϫ 10 Ϫ5 m Y-27632 compared with pregnant uterus, and the concentration-response curve was shifted rightwards (Fig. 1B) . The ID 50 values for relaxation with Y-27632 in pregnant and nonpregnant uterus were 5.2 Ϯ 0.8 and 723.9 Ϯ 2.8 m, respectively.
Effect of Rho kinase inhibitor on oxytocin-induced [Ca 2ϩ ] i mobilization
To investigate the mechanism of myometrial relaxation by Y-27632, we evaluated the effect of Y-27632 on oxytocininduced Ca 2ϩ mobilization in rat myometrial cells using a digital imaging fluorescence microscope. As shown in Fig. 2 , the addition of 0.2 m oxytocin to myometrial (d 21) cells caused a rapid and transient increase, followed by a sustained phase, in the ratio of 340/380 nm fura-2 fluorescences, indicating an increase of [Ca 2ϩ ] i (first peak). The initial component is thought to be caused by Ca 2ϩ release from internal stores, whereas the sustained phase is thought to be due to Ca 2ϩ influx across the cell membrane (31) . Pretreatment of cells with Y-27632 (10 Ϫ4 m) for 10 min did not affect the oxytocin-induced increase of [Ca 2ϩ ] i (second peak) in Fig. 2 . This was the case for pretreatment with Y-27632 for more than 10 min (data not shown). These results suggest that Y-27632 inhibited oxytocin-induced uterine contraction without a reduction of [Ca 2ϩ ] i . As a negative control, identical cells were superfused in Ca 2ϩ -free, 0.5 mm EGTAcontaining solution before activation by oxytocin. As shown in the third peak, the initial Ca 2ϩ transient was still present with about 80% magnitude, whereas the sustained Ca 2ϩ rise was absent. This is coincidence with the previous report by Arnaudeau et al. (32) .
Phosphorylation of MLC and MBS
Recent studies have revealed important roles of the RhoA/ Rho-kinase cascade in Ca 2ϩ -independent regulation of smooth muscle contraction (33, 34); this pathway modulates the level of phosphorylation of MLC, mainly through inhibition of myosin phosphatase. We therefore examined whether this pathway is involved in the mechanism of oxytocin-induced uterine contraction. First, we examined the effects of oxytocin and Y-27632 on MLC phosphorylation. As shown in Fig. 3A , the phosphorylation of MLC was increased by oxytocin (0.2 nm), without any change in the level of immunoreactive MLC. Y-27632 (10 Ϫ5 m) reduced the extent of MLC phosphorylation induced by oxytocin. Quantitative analysis showed that oxytocin induced significant increase of MLC phosphorylation, which was reduced significantly by Y-27632 (Fig. 3B) . As Y-27632 did not inhibit oxytocin-induced Ca 2ϩ mobilization in myometrial cells (Fig. 2) , it is likely that the reduction of the phosphorylation of MLC by Y-27632 occurred without changing the [Ca 2ϩ ] i level. Next, to examine how Y-27632 affected MLC phosphorylation, we evaluated the effects of oxytocin and Y-27632 on MBS phosphorylation of myosin phosphatase. One of the major sites of phosphorylation of MBS by Rho-kinase has been identified as Ser854, and we used an antibody that specifically recognizes MBS phosphorylated at Ser854 (26) . Immunoblotting with this antibody revealed that the phosphorylated form of MBS increased with oxytocin (0.2 nm) treatment compared with the untreated control (Fig. 4A) . Y-27632 (10 Ϫ5 m) reduced the extent of MBS phosphorylation induced by oxytocin without any change in the level of immunoreactive MBS. Quantitative analysis indicated that oxytocin caused a significant increase of MBS phosphorylation and that this enhancement of MBS phosphorylation was significantly inhibited by Y-27632 (Fig. 4B) . It seemed that there was a highly positive correlation between the extent of MBS phosphorylation and that of oxytocin-induced contraction.
Expression of RhoA/Rho-kinase transcripts during pregnancy
To detect the level of expression of RhoA and Rho-kinase during pregnancy, we first examined the expression of RhoA and Rho-kinase at the protein level by immunoblot analysis using protein samples prepared from the uteri of nonpregnant and pregnant (d 12, 18, 21) rats. As shown in Fig. 5A , RhoA and Rho-kinase were clearly expressed in the myometrium. Quantitative analysis showed that the amount of Rho-kinase protein expression showed a significant increase at d 18 and 21 (Fig. 5B) , whereas RhoA protein expression during pregnancy remained constant at the nonpregnant level. This result is consistent with the previous report by Moore et al. (23) .
We then examined the expression of RhoA and Rho-kinase at the mRNA level by RT-PCR. Figure 6A shows the expression of RhoA, Rho-kinase, and GAPDH mRNAs in the rat myometrium as determined by RT-PCR using the total RNA prepared from the uteri of nonpregnant and pregnant (d 12, 18, 21) rats. Bands with the expected sizes for the RhoAspecific product were clearly detected at similar levels in nonpregnant and pregnant uterine tissues. The Rho-kinasespecific product could hardly be detected in the nonpregnant myometrium but was increased and could clearly be detected at d 18 and 21. To confirm these changes of mRNA expression determined by RT-PCR analysis, we further analyzed the level of expression of RhoA and Rho-kinase mRNAs by Northern blot analysis. As shown in Fig. 6B , RhoA (2.3 and 1.8 kb) and Rho-kinase (7.6, 6.6, and 5.6 kb) transcripts were detected, and the sizes of these transcripts were the same as previously reported elsewhere (35) (36) (37) . Quantitative analysis showed that the level of expression of mRNA hybridizing with the Rho-kinase-specific probe in nonpregnant uterus was quite low, but it increased significantly during the course of pregnancy, especially at d 18 (4.6 Ϯ 0.7-fold) and d 21 (7.1 Ϯ 0.6-fold) (Fig. 6C) . However, the level of expression of mRNA hybridizing with the RhoA probe did not change during pregnancy (Fig. 6, B and C) . These results of Northern blot analysis showed that the expression of Rho-kinase mRNA in the myometrium is minimal in the nonpregnant state, and up-regulated during pregnancy, which is in agreement with the immunoblot (Fig. 5) and RT-PCR (Fig. 6A) data. These data indicate that the expression of Rho-kinase is up-regulated during pregnancy at the transcriptional level.
Discussion
In the uterine smooth muscle contraction, the phosphorylation of MLC plays an important role (31) , and an increase in phosphorylated MLC has been shown to occur in the human myometrium during contraction (38) . Oxytocin is one of the powerful agonists of uterine contraction, and exerts its effects through the G protein-coupled receptor via changes of [Ca 2ϩ ] i , as in other smooth muscles, but [Ca 2ϩ ] i is not the only determinant of mechanical activity of myometrial smooth muscle (39) , and the relationship between [Ca 2ϩ ] i and force may not be simple (40, 41) . It has become clear that agonists can increase the sensitivity for Ca 2ϩ in pregnant rat myometrium (4). It has also been shown that oxytocin can elicit uterine smooth muscle contraction even in Ca 2ϩ -free solution (42, 43) .
The novel findings of the present study are that (1) oxytocin-induced contraction was associated with enhanced MBS phosphorylation, which presumably resulted in the inhibition of myosin phosphatase and thereby induced uterine smooth muscle contraction (2), Rho-kinase mediated this MBS phosphorylation, and (3) the expression of Rho-kinase was up-regulated during pregnancy.
We used Y-27632, a pyrimidine derivative that is a specific inhibitor of the Rho-kinase (44) , to determine the role of the RhoA/Rho-kinase cascade in oxytocin-induced myometrial contraction. Y-27632 inhibited oxytocin-induced pregnant rat uterine contraction in a concentration-dependent manner. In accordance with the inhibitory effect on oxytocin-induced myometrial contraction, immunoblot analysis showed that the oxytocin-induced increase in MLC and MBS phosphorylation was significantly inhibited by Y-27632. The concentration of Y-27632 used in this study was similar to that showing antihypertensive effects in hypertensive rat models (44) . These results indicate that the activation of Rho-kinase and the phosphorylation of MBS and MLC occur concomitantly during oxytocin-induced uterine contraction, and suggest that the RhoA/Rho-kinase pathway may have an important role in enhancing contractility by increasing the phosphorylation of MLC as a result of the inhibition of myosin phosphatase by its phosphorylation.
The mechanisms controlling the transition to the increased uterine contractility at the onset of labor are still largely undefined. Many compounds such as PGs, oxytocin, and ␤-adrenoceptor agonists have been implicated in the control of uterine contractility. These agonist-receptor interactions require the participation of a member of the heteromeric G protein family. Previous reports have suggested that a change in the expression of heteromeric G proteins might be involved in the control of uterine activity in humans and guinea pigs (20, 21) . However, it is so far unknown whether low molecular weight G proteins may also be involved in the mechanism that increases the uterine contractility.
In the present study, we demonstrated that the expression of Rho-kinase mRNA was significantly up-regulated in the myometrium during pregnancy. The relaxant effects of Rhokinase inhibitor Y-27632 were increased significantly in the d 21-pregnant rat uterus compared with the nonpregnant uterus (Fig. 1B) . Niiro et al. (22) reported that the expression of RhoA and Rho-kinase mRNAs in the pregnant rat myometrium increased in comparison with that in the nonpregnant myometrium. It was also reported that stimulation of RhoA signaling in human pregnant myometrial tissue with lysophosphatic acid increased the level of MLC phosphorylation, which was inhibited by preincubation of the tissue with C3 transferase, a specific inhibitor of Rho (23) . These results, together with our present data, suggest that RhoA/ Rho-kinase pathway has an important role in oxytocin-induced uterine contraction. Moreover, the up-regulation of Rho-kinase in late pregnancy raises the possibility that not only the heteromeric G proteins (20, 21) but also RhoA/Rhokinase pathway, one of low molecular weight G proteins, may be involved in the mechanism underlying the increased contractility of the pregnant myometrium.
No rescue experiment was done on Y-27632-treated uterine strips in the present study. Also, no direct methods are available to assay Rho-kinase activity in living myometrial cells or tissues. Thus, it remains possible that inhibition of other serine-threonine protein kinases in addition to Rhokinase may also have contributed to the effects of Y-27632 observed in the present study. It is also possible that upstream pathways other than RhoA activate Rho-kinase in myometrial cells, because RhoA is not the only possible activator of Rho-kinase (45) . These issues should be addressed in future studies.
If it is assumed that oxytocin induces uterine contraction through Ca 2ϩ -dependent and Ca 2ϩ -independent pathway, our results suggests that the latter pathway is, at least in part, induced through RhoA/Rho-kinase cascade. However, to conclude that RhoA/Rho-kinase cascade is responsible for this Ca 2ϩ -independent effect of oxytocin, our findings should be strengthened by additional analysis with permeabilized tissues in which [Ca 2ϩ ] i can be manipulated freely. Future studies will be directed toward clarifying this specificity.
Spontaneous preterm labor remains a major obstetric problem because of the high incidence of associated perinatal mortality and morbidity (46) . The drugs available for the management of preterm labor are only poorly effective and have potentially serious side effects for the mother or fetus. ␤-adrenoceptor agonists, the drugs most widely used for the suppression of preterm uterine contraction, do not significantly modify the ultimate perinatal outcome, because of insufficient tissue selectivity and the resultant metabolic and cardiovascular side effects (47) (48) (49) . Therefore, it is necessary to search for new drugs that are more effective and selective. For that purpose, new developments in our understanding of the cellular mechanisms involved in uterine contractions of preterm labor are essential and will lead to more selective therapy. The present study may provide insight into possible treatment strategies involving RhoA/Rho-kinase pathway. Hitherto, little has been known about the significance of the RhoA/ Rho-kinase system in vivo because specific Rho inhibitors, such as botulinum C3 exoenzyme and Rho GDP dissociation inhibitor, are difficult to use, or not permitted for in vivo use. Y-27632 is very promising in that sense because its clinical application for the treatment of asthma, glaucoma and cancer metastasis is now under investigation (50 -52) . After application of the maximum dose of Y-27632 (10 Ϫ4 m), we observed that contractility was reversed immediately by washing the strips with medium containing oxytocin. This reversibility seems promising for in vivo applications. This agent may be useful as a uterine relaxant for the prevention of premature delivery, which is a major cause of perinatal mortality and morbidity, although much research is needed to further define the cellular, biochemical, and molecular bases for these physiological processes involved in the regulation of uterine smooth muscle contraction and relaxation. Future studies should evaluate whether Y-27632 is effective in in vivo models of labor or preterm labor.
In summary, we demonstrated that Rho-kinase expression is up-regulated in the myometrium during pregnancy and mediates uterine contractility by inhibiting myosin phosphatase through MBS phosphorylation. The detailed molecular ϩ RNAs were prepared from uteri of nonpregnant (np), d 12-pregnant (day12), d 18-pregnant (day18), and d 21-pregnant (day21) rats. The RNA samples were electrophoresed and hybridized with RhoA, Rho-kinase, and GAPDH cDNA probes. mRNA for GAPDH was probed as a control to monitor the loading of RNA. Data are representative of three independently performed experiments. C, Relative expression levels of RhoA and Rho-kinase mRNAs at each gestational stage. The radioactivity of each band was quantified using a BAS2000 imaging system. The densitometric values were normalized to GAPDH mRNA, and the density of the nonpregnant bands was set arbitrarily at 1.0. Values shown represent the mean Ϯ SEM from three separate experiments. *, P Ͻ 0.05 compared with nonpregnant samples.
mechanism of the up-regulation of Rho-kinase must be further examined in future studies.
